Approximately 1 million women aged 20 to 74 years in surgical menopause. Each year in France, 70 000 women undergoing hysterectomy for various medical reasons (endometriosis, uterine fibroids, uterine prolapse, gynecologic cancers ...). Although in most cases, conservation of the ovaries is the preferred option over the age of the patient, the more risks of complications increase ... and more oophorectomy (removal of ovaries) are used. Thus, beyond 50 years, only 37% of women keep their ovaries hystérectomiées.
An operation that is not without consequences hormonal, sexual, and therefore 50% of surgically menopausal women experiencing low libido. And for good reason: in the absence of ovaries, the amount of hormones diminishes, or libido is partly a matter of hormones, including androgens (testotérones). The estrogen replacement therapy contributes to maintain conditions conducive to sex - vaginal lubrication, in particular - but the effects are very limited sexual desire itself, the lab says Procter & Gamble. The latter has put on the market last February Intrisa, a patch releasing a low dose of testosterone, a hormone naturally present in very small quantities in women, but is secreted more or very little, if ovariectomy, inducing a loss of pleasure.
In a statement, Afssaps recalls some recommendations: "Intrinsa is only indicated for the treatment of the decline of sexual desire in women who underwent removal of the ovaries and uterus (surgically induced menopause) in association with a estrogénothérapie , especially when the decline of desire leads to personal suffering. " The Agency also points out that Intrinsa is "not recommended for women over 60 years, or in women whose menopause occurred naturally. "In addition, various side effects have been observed during clinical trials: reactions in the area of application, weight gain as well as acne, hair loss, an excessive hair or a deep voice.
An operation that is not without consequences hormonal, sexual, and therefore 50% of surgically menopausal women experiencing low libido. And for good reason: in the absence of ovaries, the amount of hormones diminishes, or libido is partly a matter of hormones, including androgens (testotérones). The estrogen replacement therapy contributes to maintain conditions conducive to sex - vaginal lubrication, in particular - but the effects are very limited sexual desire itself, the lab says Procter & Gamble. The latter has put on the market last February Intrisa, a patch releasing a low dose of testosterone, a hormone naturally present in very small quantities in women, but is secreted more or very little, if ovariectomy, inducing a loss of pleasure.
In a statement, Afssaps recalls some recommendations: "Intrinsa is only indicated for the treatment of the decline of sexual desire in women who underwent removal of the ovaries and uterus (surgically induced menopause) in association with a estrogénothérapie , especially when the decline of desire leads to personal suffering. " The Agency also points out that Intrinsa is "not recommended for women over 60 years, or in women whose menopause occurred naturally. "In addition, various side effects have been observed during clinical trials: reactions in the area of application, weight gain as well as acne, hair loss, an excessive hair or a deep voice.
